ClinicalTrials.gg
CompletedNCT02175017Updated Dec 9, 2024Results posted

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

A Phase 2 interventional study of ONO-4538 and ONO-4538 in Advanced Non-small Cell Lung Cancer (NSCLC), sponsored by Ono Pharmaceutical Co. Ltd. Completed at 10 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
43rd of 120
104 · median 66
Started
2014
with 4 others
Phase 2
66 of 120
16 open now
Registered
11th of 120
by date
Lead sponsor
3 of 120
Ono Pharmaceutical Co. Ltd

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 43rd largest by enrollment, is one of 5 that started in 2014, is one of 66 in phase 2, and was the 11th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The objective of the study is to investigate the efficacy and safety of ONO-4538 in subjects with stage IIIB/IV or recurrent non-small cell lung cancer unsuited to radical radiotherapy and resistant to a platinum-based chemotherapeutic regimen.

03

Conditions studied

  • Advanced Non-small Cell Lung Cancer (NSCLC)

Keywords

  • ONO-4538
  • Advanced non-small cell lung cancer (NSCLC)
  • nivolumab
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥ 20 years of age
  2. or cytologically confirmed non-small cell lung cancer
  3. Diagnosis of NSCLC in stage IIIB/IV unsuited to radical radiotherapy according to UICC-TNM classification (7th edition) or recurrent NSCLC
  4. Has at least one , as defined by the guideline (version 1.1)

Exclusion criteria

Exclusion Criteria:

  1. Current or prior severe to another antibody product
  2. Multiple primary cancers
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    ONO-4538 for squamous non-small-cell lung cancer (NSCLC)

    In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.

    Drug: ONO-4538

  • Experimental
    ONO-4538 for non-squamous non-small-cell lung cancer (NSCLC)

    In each treatment cycle, patients received an intravenous infusion of nivolumab (ONO-4538) at a dose of 3 mg/kg every 2 weeks for 6 weeks. Changes in dose were not allowed. Radiological assessments (computed tomography/ magnetic resonance imaging) were conducted every 6 weeks. Patients entered subsequent treatment cycles unless they met discontinuation criteria, including disease progression, unacceptable adverse events, and consent withdrawal. Patients who were discontinued for any of these reasons entered the follow-up phase.

    Drug: ONO-4538

Interventions

  • ONO-4538 Study in Patients With Squamous NSCLC

    Also known as: nivolumab

  • ONO-4538 Study in Patients With Non-Squamous NSCLC

    Also known as: nivolumab

06

What researchers measure

Primary outcomes

  1. Response Rate (Centrally Assessed)

    Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\*100. 95% Confidence interval (CI) was calculated by Wilson method.

    Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.

Secondary outcomes

  1. Response Rate (Investigator-assessed)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

    Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.

  2. Overall Survival

    Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.

    Time frame: Follow-up phase: Every 6 months after the first day of treatment of the last subject enrolled in the study, until death or study completion.

  3. Progression Free Survival (Centrally Assessed)

    Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.

    Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or until central PD was confirmed or data cut-off point.Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.

  4. Duration of Response (Centrally Assessed)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.

    Time frame: Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase(up to approximately 10 months).Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.

07

Results

Posted Dec 9, 2024

Participant flow

Participant flow — Overall Study
MilestoneSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Started4558
Completed1215
Not completed3343
Withdrew: Did not receive the investigational product12
Withdrew: Withdrawal by subject63
Withdrew: Met an exclusion criteria01
Withdrew: Adverse event310
Withdrew: Disease progression2027
Withdrew: Other than above reasons30

Outcome measures

PrimaryResponse Rate (Centrally Assessed)

Response rate (%) = (Number of subjects whose confirmed best overall response was complete response (CR) or partial response (PR) / Total number of FAS)\*100. 95% Confidence interval (CI) was calculated by Wilson method.

Time frame:
Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.
Reported as:
Number · percentage of participants
Response Rate (Centrally Assessed)
percentage of participantsSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Response Rate (Centrally Assessed)13.6 (6.4 to 26.7)19.6 (11.3 to 31.8)
SecondaryResponse Rate (Investigator-assessed)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Time frame:
Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase (up to approximately 10 months).Follow-up phase: 28 days after final dose or for discontinuation occurring 28 or fewer days after final dose.
Reported as:
Number · percentage of participants
Response Rate (Investigator-assessed)
percentage of participantsSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Response Rate (Investigator-assessed)18.2 (9.5 to 32.0)19.6 (11.3 to 31.8)
SecondaryOverall Survival

Overall survival (days) = (the date of death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.

Time frame:
Follow-up phase: Every 6 months after the first day of treatment of the last subject enrolled in the study, until death or study completion.
Reported as:
Median · days
Overall Survival
daysSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Overall SurvivalNA (249.0 to NA)NA (291.0 to NA)
SecondaryProgression Free Survival (Centrally Assessed)

Progression free survival (days) = (the earlier date of the first documented progressive disease (PD) or death due to any cause) - (the first dose date of investigational product) + 1. 95% CI was calculated by Kaplan-Meier method.

Time frame:
Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or until central PD was confirmed or data cut-off point.Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.
Reported as:
Median · days
Progression Free Survival (Centrally Assessed)
daysSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Progression Free Survival (Centrally Assessed)67.0 (41.0 to 182.0)162.0 (43.0 to 216.0)
SecondaryDuration of Response (Centrally Assessed)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Duration of response (days) = (the date of the first documented PD or death due to any cause after response was confirmed) - (the date of the first confirmed CR or PR) + 1. Median (95% CI) was calculated by Kaplan-Meier method.

Time frame:
Screening phase: Up to 14 days before enrollment.Treatment phase: Day 43 of each cycle or end of treatment phase(up to approximately 10 months).Follow-up phase: Until beginning subsequent treatment for non-small cell lung cancer or PD or recurrence.
Reported as:
Median · days
Duration of Response (Centrally Assessed)
daysSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Duration of Response (Centrally Assessed)NA (145.0 to NA)NA (85.0 to NA)

Adverse events

Collected over From the start of the first dose of the investigational product to 28 days after the final dose or discontinuation, occurring 28 or fewer days after the final dose, or data cut-off point (June 2, 2015), whichever occurs first. Adverse events will be monitored and assessed before each dose and as needed based on clinical symptoms. Total assessment period: up to 10 months per participant.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Squamous Non-small Cell Lung Cancer (NSCLC)12/44 (27.3%)20/44 (45.5%)24/44 (54.5%)
Non-squamous Non-small Cell Lung Cancer (NSCLC)15/56 (26.8%)17/56 (30.4%)36/56 (64.3%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
PneumoniaInfections and infestations5/444/56
HypercalcaemiaMetabolism and nutrition disorders3/440/56
DyspnoeaRespiratory, thoracic and mediastinal disorders1/443/56
PyrexiaGeneral disorders2/440/56
PneumonitisRespiratory, thoracic and mediastinal disorders1/442/56
Angina unstableCardiac disorders1/440/56
DiarrhoeaGastrointestinal disorders1/440/56
Inguinal herniaGastrointestinal disorders1/440/56
Lung infectionInfections and infestations1/441/56
Subdural haemorrhageInjury, poisoning and procedural complications1/440/56
Most frequent other events
Showing 10 of 31
Most frequent other events
EventSquamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)
Decreased appetiteMetabolism and nutrition disorders18/4420/56
CoughRespiratory, thoracic and mediastinal disorders12/4415/56
DyspnoeaRespiratory, thoracic and mediastinal disorders11/4415/56
PruritusSkin and subcutaneous tissue disorders6/4412/56
Productive coughRespiratory, thoracic and mediastinal disorders9/449/56
ConstipationGastrointestinal disorders8/4411/56
FatigueGeneral disorders7/4411/56
PyrexiaGeneral disorders7/448/56
DiarrhoeaGastrointestinal disorders6/442/56
NauseaGastrointestinal disorders6/446/56

Baseline characteristics

Age, Continuous
Age, Continuous(years)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
Median69.5 (40 to 80)63.5 (29 to 77)66.5 (29 to 80)
Age, Customized
Age, Customized(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
<65 years143044
65-<75 years212041
>=75 years9615
Sex: Female, Male
Sex: Female, Male(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
Female02222
Male443478
Region of Enrollment
Region of Enrollment(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
South Korea4456100
Histology
Histology(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
Squamous44044
Adenocarcinoma05050
Large cell carcinoma011
Other055
Disease stage
Disease stage(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
IIIB516
IV375491
Recurrent213
Prior treatment for NSCLC: Surgery
Prior treatment for NSCLC: Surgery(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
Yes9918
No354782
Prior treatment for NSCLC: Radiotherapy
Prior treatment for NSCLC: Radiotherapy(Participants)Squamous Non-small Cell Lung Cancer (NSCLC)Non-squamous Non-small Cell Lung Cancer (NSCLC)Total
Yes111324
No334376

7 further baseline measures are reported on the registry.

08

Study locations

10 sites
  • Cheongju-si Clinical Site 106
    Cheongju-si, Chungcheongbuk-do, Korea, Republic of
  • Goyang-si Clinical Site 103
    Goyang-si, Gyeonggi-do, Korea, Republic of
  • Seongnam-si Clinical Site 104
    Seongnam-si, Gyeonggi-do, Korea, Republic of
  • Incheon Clinical Site 102
    Incheon, Korea, Republic of
  • Seoul Clinical Site 101
    Seoul, Korea, Republic of
  • Seoul Clinical Site 107
    Seoul, Korea, Republic of
  • Seoul Clinical Site 108
    Seoul, Korea, Republic of
  • Seoul Clinical Site 109
    Seoul, Korea, Republic of
  • Seoul Clinical Site 110
    Seoul, Korea, Republic of
  • Ulsan Clinical Site 105
    Ulsan, Korea, Republic of
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Data sharing details ↗ · www.ono.co.jp

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Nov 2015, 17 months.

Results were first posted in Dec 2024, 9 years 1 month after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 17 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2014
First posted
Jun 26, 2014
StartActual
Jun 2014
Primary completionActual
Nov 2015
CompletionActual
Feb 2021
Results first posted
Dec 9, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02175017
Responsible party
Sponsor
First posted
Jun 26, 2014
Start date
Jun 2014
Primary completion
Nov 2015
Completion
Feb 2021
Results posted
Dec 9, 2024
Last update
Dec 9, 2024

Study contacts

Mitsunobu Tanimoto
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion